Global InformationKP1019 information
 KP1019 Chemical Structure | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous (as a sodium salt, KP1339) |
| Identifiers | |
IUPAC name
| |
| UNII |
|
| ChEBI |
|
| Chemical and physical data | |
| Formula | C21H19Cl4N6Ru |
| Molar mass | 598.29 g·mol−1 |
KP1019, or indazole trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is one of four ruthenium anti-cancer drugs to enter into phase I clinical trials, the others being BOLD-100, NAMI-A and TLD-1433. Research into ruthenium-based drugs has provided novel alternatives for platinum-based chemotherapeutics such as Cisplatin and its derivatives. KP1019 is useful for metastatic tumors and cis-platin resistant tumors. It exhibits potent cytotoxicity against primary tumors, particularly in colorectal cancer.[1]
- ^ Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, Keppler BK (October 2008). "KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients". Chemistry & Biodiversity. 5 (10): 2140–55. doi:10.1002/cbdv.200890195. PMID 18972504. S2CID 205544866.